

(21) Application No: 1420267.5
(22) Date of Filing: 24.10.2014
Date Lodged: 05.12.2014

(30) Priority Data:
(31) 1318880.0 (32) 25.10.2013 (33) GB
(31) 1318885.9 (32) 25.10.2013 (33) GB
(31) 1322851.5 (32) 23.12.2013 (33) GB
(31) 1401159.7 (32) 23.01.2014 (33) GB
(31) 1406470.3 (32) 10.04.2014 (33) GB

(86) International Application Data:
PCT/EP2014/072919 En 24.10.2014

(87) International Publication Data:
WO2015/059303 En 30.04.2015

(71) Applicant(s):
Psioxus Therapeutics Limited
154B Milton Park, ABINGDON, Oxfordshire,
OX14 4SD, United Kingdom

(72) Inventor(s):
Brian Robert Champion
Alice Claire Noel Brown
Kerry David Fisher
Tamara Jane Nicolson

(74) Agent and/or Address for Service:
Sterling IP
Orion House, Bessemer Road, Welwyn Garden City,
Hertfordshire, AL7 1HH, United Kingdom

(51) INT CL:
C12N 7/00 (2006.01) A61K 35/761 (2015.01)
A61K 48/00 (2006.01) C12N 15/861 (2006.01)

(56) Documents Cited:
WO 2006/060314 A WO 2005/118825 A
WO 2005/086922 A
PLoS ONE (2008); Vol 3, Art. e2409, "Directed evolution generates a novel oncolytic...", Kuhn et al Proc. Natl. Acad. Sci. USA (2009); Vol 106, pp 12915-12920, "Anti-VEGF single chain antibody GLAF-1...", Frentzen et al Gene Therapy (2012); Vol 19, pp 988-998, "Targeted cancer immunotherapy with oncolytic adenovirus...", Dias et al Journal of Clinical Investigation (2000); Vol 105, pp 169-1172, "Gene delivery from replication-selective viruses...", Hermiston "Improving oncolytic adenoviral therapies..." (2010). Kangasniemi; URL <https://helda.helsinki.fi/bitstream/handle/10138/20501/improvin.pdf?sequence+1>

(58) Field of Search:
INT CL A61K, C12N
Other: EPO-Internal, EMBL, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

(54) Title of the Invention: **Oncolytic adenoviruses armed with heterologous genes**
Abstract Title: **Oncolytic adenoviruses armed with heterologous genes**

(57) The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5'ITR-B1-BA-B2-BX-BB-BY-B3-3'ITR wherein: B1 is a bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.

Figure 37

